In summary, CCL2 knockdown through delivery of Ca-TAT/siRNA complexes could be an effective treatment strategy for the treatment of invasive breast cancer, particularly when combined with other anti-cancer therapies. The gene discussed is CCL2; the disease is invasive breast carcinoma.